Engineering S. typhimurium for metastatic colorectal cancer

工程鼠伤寒沙门氏菌治疗转移性结直肠癌

基本信息

  • 批准号:
    9973552
  • 负责人:
  • 金额:
    $ 34.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-06-15 至 2024-09-30
  • 项目状态:
    已结题

项目摘要

The engineering of living cells and microbes is driving a new era of cancer therapy. This transformative approach allows for the genetic programming of living cells to intelligently sense and respond to environments, ultimately adding specificity and efficacy that is otherwise unattainable with molecular-based therapeutics. Due to recent microbiome studies indicating the prevalence of bacteria within the human body and specifically in tumor tissue, bacteria have generated significant interest as cancer therapies. Additionally, a multitude of empirical studies have demonstrated that administered bacteria home and selectively grow in tumors due to reduced immune surveillance of tumor cores. Given their presence and selectivity for tumors, bacteria present a unique oppor- tunity to be engineered as intelligent delivery vehicles for cancer therapy. The objective of this proposal is to engineer and optimize S. typhimurium for metastatic colorectal cancer therapy. Since animal based-testing regimes limit the rate of clinical progress, we will use a high-throughput, bacteria-spheroid platform to rapidly test therapeutic payloads and production and release strategies. We will also assess the effect of therapies on colorectal genetic backgrounds, and investigate spatio-temporal hetero- geneity in 3D spheroids with the use of engineered cell reporters. We will then test lead candidates in mouse models of primary and metastatic colorectal cancer to evaluate safety and efficacy. We will focus on colorectal cancer due to several proof-of-concept studies from our lab demonstrating efficacy in colorectal spheroids and animal models. In particular, we showed that oral delivery of bacteria can specifically colonize colorectal liver metastases, providing an attractive delivery route as a cancer therapy. Since these metastases are often con- fined to the liver, this approach can have a significant impact on tumor growth and survival. The research in this proposal will help to establish a framework to genetically engineer microbes for cancer therapy, and significantly accelerates tools that will impact the broader cancer and synthetic biology communities. If successful, future lead candidates for potential clinical trials will be identified on the basis of therapeutic efficacy and safety studies from this proposal.
活细胞和微生物工程正在推动癌症治疗的新纪元。这种变革性的方法 最终,使活细胞的遗传编程能够智能地感知环境并做出反应 增加了以分子为基础的疗法无法获得的特异性和有效性。由于最近 微生物组研究表明细菌在人体内的流行,特别是在肿瘤组织中, 细菌作为癌症治疗方法引起了极大的兴趣。此外,大量的实证研究 已经证明,由于免疫力降低,注射的细菌会在肿瘤中回家并选择性地生长 对肿瘤核心的监测。鉴于它们的存在和对肿瘤的选择性,细菌呈现出一种独特的对立-- Tunity将被设计为癌症治疗的智能输送工具。 这项建议的目的是设计和优化鼠伤寒沙门氏菌治疗转移性结直肠癌 心理治疗。由于基于动物的试验制度限制了临床进展的速度,我们将使用高通量、 细菌-椭圆形平台,用于快速测试治疗有效载荷以及生产和释放策略。我们会 也评估治疗对结直肠遗传背景的影响,并调查时空异质性。 利用工程细胞记者对3D球体的遗传性进行研究。然后我们将在MICE中测试领先的候选人 建立原发结直肠癌和转移性结直肠癌的模型,以评估安全性和有效性。我们将重点关注结直肠 我们实验室的几项概念验证研究证明了对结直肠球体和结直肠球的疗效 动物模型。特别是,我们证明了口服细菌可以特异性地定植于结直肠肝脏。 转移,为癌症治疗提供了一条有吸引力的输送途径。因为这些转移瘤通常是 对肝脏处以罚款,这种方法可以对肿瘤的生长和生存产生重大影响。这方面的研究 该提案将有助于建立一个框架,对癌症治疗的微生物进行基因工程,并具有重要意义 加速工具,将影响更广泛的癌症和合成生物学社区。如果成功,那就是未来 将根据疗效和安全性研究确定潜在临床试验的主要候选者 从这项提议中。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tal Danino其他文献

Tal Danino的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tal Danino', 18)}}的其他基金

Engineering probiotics for tuberculosis therapy
用于结核病治疗的工程益生菌
  • 批准号:
    10511520
  • 财政年份:
    2022
  • 资助金额:
    $ 34.67万
  • 项目类别:
Engineering probiotics for tuberculosis therapy
用于结核病治疗的工程益生菌
  • 批准号:
    10629371
  • 财政年份:
    2022
  • 资助金额:
    $ 34.67万
  • 项目类别:
Probiotic guided CAR-T therapy (ProCARs) for breast cancer
益生菌引导的乳腺癌 CAR-T 疗法 (ProCAR)
  • 批准号:
    10681319
  • 财政年份:
    2020
  • 资助金额:
    $ 34.67万
  • 项目类别:
Probiotic guided CAR-T therapy (ProCARs) for breast cancer
益生菌引导的乳腺癌 CAR-T 疗法 (ProCAR)
  • 批准号:
    10034374
  • 财政年份:
    2020
  • 资助金额:
    $ 34.67万
  • 项目类别:
Engineering immunotherapeutic probiotics to mitigate irAE
工程免疫治疗益生菌以减轻 irAE
  • 批准号:
    10378953
  • 财政年份:
    2020
  • 资助金额:
    $ 34.67万
  • 项目类别:
Probiotic guided CAR-T therapy (ProCARs) for breast cancer
益生菌引导的乳腺癌 CAR-T 疗法 (ProCAR)
  • 批准号:
    10447144
  • 财政年份:
    2020
  • 资助金额:
    $ 34.67万
  • 项目类别:
Probiotic guided CAR-T therapy (ProCARs) for breast cancer
益生菌引导的乳腺癌 CAR-T 疗法 (ProCAR)
  • 批准号:
    10263960
  • 财政年份:
    2020
  • 资助金额:
    $ 34.67万
  • 项目类别:
Engineering S. typhimurium for metastatic colorectal cancer
工程鼠伤寒沙门氏菌治疗转移性结直肠癌
  • 批准号:
    10532672
  • 财政年份:
    2020
  • 资助金额:
    $ 34.67万
  • 项目类别:
Programmable Probiotics for Cancer
可编程益生菌治疗癌症
  • 批准号:
    9189187
  • 财政年份:
    2016
  • 资助金额:
    $ 34.67万
  • 项目类别:
Programmable Probiotics for Cancer
可编程益生菌治疗癌症
  • 批准号:
    9252421
  • 财政年份:
    2016
  • 资助金额:
    $ 34.67万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 34.67万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 34.67万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 34.67万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 34.67万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 34.67万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 34.67万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 34.67万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 34.67万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 34.67万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 34.67万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了